Trial · NCT07301320

Epetraborole in Patients With Mycobacterium Abscessus Lung Disease

NCT07301320, Phase 2, Recruiting, Kevin Winthrop

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Epetraborole in Patients With Mycobacterium Abscessus Lung Disease. Trials, record NCT07301320. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07301320

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Epetraborole in Patients With Mycobacterium Abscessus Lung Disease
NCT number: NCT07301320
Status: Recruiting
Phases: Phase 2
Enrollment: 84 participants, estimated
Lead sponsor: Kevin Winthrop
Conditions: Mycobacterium Abscessus Infection
Interventions: Epetraborole, Epetraborole, Placebo, Placebo
First posted: 2025-12-24
Last updated: 2026-05-06

Source ClinicalTrials.gov

Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Clinical Response (NTM Symptom Evaluation Instrument) at Day 84	Day 1 to Day 84	Improvement in severity of at least 50% of the symptoms present at baseline and no deterioration in severity of symptoms present at baseline
Primary	Sputum culture conversion by Day 84	Day 1 to Day 84	Defined as 3 consecutive negative cultures one month apart without intervening or subsequent positives
Primary	Decrease in semi-quantitative sputum culture counts at Day 84	Day 1 to Day 84	Defined as improvement in sputum colony count category as defined by Griffith et al, 2015
Primary	Change from baseline in Quality of Life - Bronchiectasis (QOL-B) Respiratory Domain at Day 84	Day 1 to Day 84	QOL-B Domain scores range from 0 to 100, with higher scores indicating better health-related quality of life
Primary	Change from baseline in MACrO2 PRO at Day 84	Day 1 to Day 84	MACrO2 scores range from 0 to 100, with lower scores indicating better symptom-related quality of life
Primary	Sputum culture conversion by Day 56	Day 1 to Day 56	Defined as 2 consecutive negative cultures collected one month apart without intervening or subsequent positives
Secondary	Patient Global Impression of Change (PGI-C) at Day 84	Day 1 to Day 84	The Patient Global Impression of Change Scale has a minimum value of 1 and a maximum value of 7. For this scale, higher scores indicate a worse outcome.
Secondary	Patient Global Impression of Severity (PGI-S) at Day 84	Day 1 to Day 84	The Patient Global Impression of Severity Scale measures severity of a patient's overall status over the previous 7 days. The responses on this scale have a minimum value of 'None' and a maximum value of 'Very severe' related to severity. For this scale, higher scores ('Very severe') indicate a worse outcome.
Secondary	Physician Visual Analog Scale (VAS) - Global at Day 84	Day 1 to Day 84	The Physician Visual Analog Scale - Global has a minimum value of 0 and a maximum value of 10. For this scale, higher scores indicate a worse outcome.
Secondary	Physician Visual Analog Scale (VAS) - Respiratory at Day 84	Day 1 to Day 84	The Physician Visual Analog Scale - Respiratory has a minimum value of 0 and a maximum value of 10. For this scale, higher scores indicate a worse outcome.

1 to 10 of 15Source ClinicalTrials.gov

See all 15 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers9

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
26068042	BACKGROUND	PubMed
28461147	BACKGROUND	PubMed
30071551	BACKGROUND	PubMed
32628747	BACKGROUND	PubMed
34314673	BACKGROUND	PubMed
35388453	BACKGROUND	PubMed
38190702	BACKGROUND	PubMed
38615375	BACKGROUND	PubMed
39016592	BACKGROUND	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07301320

GET https://conductscience.org/api/trials/v1/NCT07301320/registered

API reference For AI assistants